Xanthinuria type I is a rare genetic condition that affects how the body breaks down purines. People with xanthinuria type I often have no symptoms, but some develop kidney stones, urinary pain, or blood in the urine. It usually begins in childhood or early adulthood and is lifelong. Most people with xanthinuria type I have a normal life expectancy, but kidney problems can occur if stones block urine flow. Treatment focuses on preventing stones with high fluid intake, a low-purine diet, and sometimes medications to alkalinize urine, and doctors monitor kidney health over time.
Overview
Xanthinuria type iSymptoms
Xanthinuria type I often has no clear signs until xanthine kidney stones form. Early signs of Xanthinuria type I may include side or back pain, blood in urine, frequent or painful urination; develop recurrent stones, urinary blockages, or kidney infection.
Outlook and prognosis
Most people with Xanthinuria type I feel well and have a normal lifespan. The main long‑term issue is a higher risk of kidney stones and, less often, gout-like joint pain; staying well‑hydrated and regular monitoring help prevent complications. Genetic counseling can guide family planning.
Causes and risk factors
Xanthinuria type I is caused by changes in both copies of the XDH gene; it’s inherited autosomal‑recessively. Risk increases with consanguinity or an affected sibling. Low fluid intake and high‑purine diets may worsen stone risk.
Genetic influences
Genetics are central in Xanthinuria type i. It’s a rare inherited condition caused by variations in the XDH gene, usually passed in an autosomal recessive pattern. Genetic testing confirms diagnosis, guides family counseling, and helps identify carriers and at‑risk relatives.
Diagnosis
Genetic diagnosis of Xanthinuria type I follows labs showing very low blood uric acid and excess xanthine in urine, stone analysis, and supportive imaging such as ultrasound or CT.
Treatment and drugs
Treatment for Xanthinuria type I focuses on lowering xanthine to protect kidneys. Many do well with a low‑purine diet, generous fluids (about 2–3 liters or 68–101 ounces daily), and avoiding dehydration. Doctors may monitor urine, check kidney imaging, and manage stones promptly.
Symptoms
Day to day, most people feel well until crystals build up in the urinary tract, leading to kidney stones and related issues. Features vary from person to person and can change over time. Early features of Xanthinuria type i can be subtle, such as cloudy, gritty urine or mild muscle aches after exercise. Doctors often first spot it when uric acid is unusually low on blood or urine tests.
Many people with Xanthinuria type i feel well for years. The condition may only be noticed on routine blood or urine tests. Daily life usually isn’t affected unless stones form.
Hard deposits can form in the kidneys from xanthine crystals. They can cause sudden, sharp side or back pain with nausea. Some stones pass on their own; others need medical treatment.
Urine may look cloudy or leave fine, sand-like particles in the toilet. This comes from crystals collecting in the urine. It can come and go.
You might see pink or red urine, or a lab test finds microscopic blood. This often happens when a stone rubs or moves. Seek care if bleeding is heavy or persistent.
How people usually first notice Xanthinuria type i?
People often first notice xanthinuria type I when a child or young adult develops kidney stones that are hard to explain, sometimes passing gritty, sand-like material in the urine, or having flank or lower back pain. Doctors may pick it up after routine urine tests show very low or no uric acid with unusually high xanthine, prompting further evaluation when kidney stones recur despite typical prevention. In newborns and infants it’s rarely obvious, so the first signs of xanthinuria type I are most often repeated kidney stones and distinctive urine chemistry found during workups in childhood or later.
Types of Xanthinuria type i
Xanthinuria type I is a rare genetic condition. Variants of xanthinuria are defined by which enzyme in the purine breakdown pathway is affected, which changes how uric acid and related substances are handled in the body. People may notice different sets of symptoms depending on their situation. Here are the main types to know about:
Type I (XDH deficiency)
This classic form is caused by low or absent activity of xanthine dehydrogenase, leading to very low uric acid and high xanthine levels. Many people have no symptoms, while others develop kidney stones made of xanthine and occasional muscle pain after exercise.
Type II (XDH/aldehyde oxidase deficiency)
In this variant, both xanthine dehydrogenase and aldehyde oxidase are affected because a shared activation step is disrupted. Symptoms overlap with type I, but certain medicines and compounds that rely on aldehyde oxidase may be processed differently.
Molybdenum cofactor defect
This rare, more severe disorder affects multiple molybdenum-dependent enzymes, including xanthine dehydrogenase and sulfite oxidase. Beyond low uric acid and xanthine buildup, babies often develop neurological symptoms early in life.
Xanthine stone–predominant
Some people—across types I or II—mainly experience recurrent xanthine kidney stones despite otherwise feeling well. For many, certain types stand out more than others.
Asymptomatic biochemical
Others have low uric acid and high xanthine on lab tests but few or no day-to-day symptoms. Not everyone will experience every type.
What genetics can tell you about symptoms
Certain XDH gene variants reduce the body’s ability to break down purines, causing xanthine to build up and form kidney or bladder stones, blood in urine, or flank pain. Some people also have very low uric acid levels and muscle aches after exercise.
Causes and risk factors
Xanthinuria type i is caused by changes in the XDH gene that reduce or stop the work of the xanthine oxidase enzyme. It is usually inherited when both parents carry the change, and it can rarely arise for the first time. Some risks are modifiable (things you can change), others are non-modifiable (things you can’t). Non‑modifiable risks include a family history and parents who are related. Key risk factors for kidney stones in Xanthinuria type i include dehydration, hot weather or heavy exercise without fluids, and very high‑purine diets.
Environmental and biological risk factors
Xanthinuria type i is present from birth, so most risk comes into play before or at conception. Doctors often group risks into internal (biological) and external (environmental). At this time, there are no well-established environmental risk factors for Xanthinuria type i, and most families did nothing to cause it. When environmental influences are discussed, they are general to many congenital conditions and not confirmed for this one.
No consistent environmental exposures have been shown to raise the likelihood of Xanthinuria type i. Research to date has not identified air, water, or workplace exposures that consistently change risk.
Older paternal age at conception is linked to a small increase in the overall chance of rare conditions that start before birth. A direct connection with Xanthinuria type i has not been demonstrated.
Exposure of either parent to high-dose ionizing radiation around conception can raise the overall chance of rare conditions that begin before birth. No specific link to Xanthinuria type i has been established.
Some chemotherapy or radiation received before conception can temporarily raise the chance of certain birth conditions. Waiting periods before trying to conceive are often recommended, though this has not been directly tied to Xanthinuria type i.
Genetic risk factors
In Xanthinuria type I, changes in the XDH gene disrupt the enzyme that normally helps break down certain natural substances, leaving uric acid very low and xanthine higher than usual. The condition follows an autosomal recessive pattern, meaning a person is affected when both copies of the XDH gene have a disease-causing change and parents are usually healthy carriers. Genetic testing for Xanthinuria type I can confirm the cause and help identify carrier relatives. Risk is not destiny—it varies widely between individuals.
XDH gene variants: XDH gene variants reduce or stop the xanthine dehydrogenase enzyme from working. This is the direct genetic cause of Xanthinuria type I. Different variants can lead to different amounts of enzyme activity.
Autosomal recessive: Two changed copies of XDH—one inherited from each parent—are needed to develop the condition. Parents with one changed copy are typically healthy carriers. This explains why it can appear unexpectedly in a family.
Carrier parents: When both parents are carriers, each pregnancy has a 25% chance (1 in 4) of Xanthinuria type I. There is also a 50% chance the child will be an unaffected carrier. A genetics professional can walk through these odds and testing options.
Family history: Having a sibling or close relative with the condition raises the chance of carrying the same XDH variant. Testing relatives, sometimes called cascade testing, can identify carriers before problems arise. This information can guide future family planning.
Parental relatedness: Parents who are related by blood are more likely to share the same rare XDH variant. This increases the chance their children inherit two changed copies and develop the condition. Families may wish to discuss screening with a genetics clinic.
Founder variants: In some families or regions, a shared XDH change passed down from a distant ancestor (a founder effect) makes the condition more frequent. If a known founder variant exists in your community, targeted testing may be available. Local genetics services can advise on the best approach.
Genetic testing: Sequencing the XDH gene can confirm Xanthinuria type I and pinpoint the exact variant. Results help tailor testing for relatives and options for future pregnancies. For some, this provides clearer answers than urine or blood chemistry alone.
Lifestyle risk factors
Xanthinuria type i is a genetic disorder of purine breakdown; lifestyle habits do not cause it but can influence stone formation, symptoms, and complications. Practical choices can reduce urinary xanthine concentration, improve solubility, and limit triggers for crystallization. Here’s how lifestyle affects Xanthinuria type i, highlighting key lifestyle risk factors for Xanthinuria type i. Discuss personalized targets with your care team.
Consistently high fluid intake dilutes urinary xanthine and lowers stone risk. Increase fluids during heat, illness, or exercise to keep urine pale.
Limiting organ meats, certain fish (like anchovies/sardines), and rich meat broths reduces xanthine generated from purine metabolism. Emphasize plant-forward proteins to lessen purine load.
Fruits, vegetables, and citrate-containing drinks (lemon/lime water) can raise urine pH and citrate, improving xanthine solubility. Reducing acid-producing animal protein helps avoid overly acidic urine.
Methylxanthines in coffee, energy drinks, and cocoa may add to urinary xanthine and can promote dehydration. Limiting these sources may help people prone to stones.
Risk prevention
Xanthinuria type I can’t be prevented at its root, so the goal is to lower the chance of kidney stones and protect kidney function over time. Day-to-day steps like steady hydration, low‑purine eating, and avoiding certain medicines can reduce xanthine buildup. Prevention works best when combined with regular check-ups. Knowing early symptoms of xanthinuria type i—like flank pain, blood in the urine, or passing gritty, sand-like stones—can help you seek care quickly.
Drink enough to keep urine pale and plentiful, typically 2–3 liters (68–101 oz) of fluids per day. Extra fluids are often needed in hot weather or with exercise to prevent xanthine from concentrating.
Limiting purine-heavy foods lowers xanthine production and stone risk in Xanthinuria type I. Work with a dietitian to reduce organ meats, certain fish (like anchovies and sardines), and large portions of red meat.
Your clinician may suggest alkali (like potassium citrate) to raise urine pH and improve xanthine solubility. This is prescribed and monitored to balance benefits with your overall kidney health.
Avoid xanthine‑oxidase blockers (such as allopurinol or febuxostat) unless a specialist advises otherwise, as they can increase xanthine buildup in Xanthinuria type I. Always check new medicines and supplements with your care team.
Transmission
Xanthinuria type i is a genetic condition and isn’t contagious—you can’t catch it through touch, air, food, sex, or blood. It follows an autosomal recessive pattern: a child develops Xanthinuria type i when they inherit two nonworking copies of the gene, one from each parent. Parents who each carry one nonworking copy are typically healthy carriers; with every pregnancy there’s a 25% (1 in 4) chance of having a child with Xanthinuria type i, a 50% (1 in 2) chance the child will be a carrier, and a 25% chance the child will inherit neither change. Most cases happen when both parents are carriers, though a new gene change can rarely occur; if you’re wondering about the genetic transmission of Xanthinuria type i, a genetics professional can explain how Xanthinuria type i is inherited in your family.
When to test your genes
Test your genes if you have recurrent kidney stones, very low uric acid, muscle pain after exercise, or reddish-brown urine, especially if these start in childhood or run in your family. Genetic testing helps confirm xanthinuria type I, guides a low-purine diet and hydration plan, and avoids unnecessary gout medicines. Consider testing before pregnancy or if a close relative is diagnosed.
Diagnosis
Xanthinuria type i is usually picked up when someone has kidney stones that don’t show on standard X-rays, or when routine blood work finds very low uric acid. Doctors often confirm the diagnosis with a mix of blood and urine tests, imaging, and—when available—genetic testing. Genetic testing may be offered to clarify risk or guide treatment. Putting these pieces together helps distinguish this rare condition from more common causes of kidney stones and low uric acid.
Recurrent kidney stones, blood in the urine, or gritty crystals in diapers can be early clues. Some notice muscle pain after exercise or flank pain during a stone episode. These patterns prompt a closer look for xanthinuria.
A very low or undetectable uric acid level in the blood with otherwise normal kidney function raises suspicion. This finding is uncommon and helps focus testing toward xanthine disorders.
Urine testing shows high xanthine and hypoxanthine with very low uric acid. Specialized labs can measure these compounds to support the diagnosis.
If a stone is passed or removed, laboratory analysis can confirm it is made of xanthine. This distinction matters because xanthine stones are managed differently than uric acid or calcium stones.
Stages of Xanthinuria type i
Xanthinuria type i does not have defined progression stages. It tends to be stable, and symptoms usually come and go based on whether crystals or kidney stones are present rather than following a steady decline; early symptoms of Xanthinuria type i often appear only when stones form. Different tests may be suggested to help confirm the diagnosis, such as very low uric acid levels in blood and urine, finding excess xanthine on urine testing or stone analysis, imaging for stones, and sometimes genetic testing. Ongoing care typically involves periodic checks of kidney function, urine assessments, and imaging if pain, blockage, or recurrent stones are suspected.
Outlook and prognosis
Many people ask, “What does this mean for my future?”, especially after a new diagnosis of Xanthinuria type I. For most, the long‑term outlook is favorable. Many people with Xanthinuria type I have few or no symptoms, and the condition is often found by chance on urine tests or after a kidney stone. When symptoms do show up, they usually involve kidney stones, urinary discomfort, or occasional joint aches due to crystal deposits. Doctors call this the prognosis—a medical word for likely outcomes.
Looking at the long-term picture can be helpful. Xanthinuria type I itself is not linked to shortened life expectancy, and mortality directly from the condition is rare. The biggest risks come from repeated stones and blockages that can, over years, strain the kidneys. Early care can make a real difference, because staying well hydrated, moderating meat intake, and promptly treating stones can lower the chance of kidney damage. People living with Xanthinuria type I who keep up with routine checks of kidney function and imaging when needed usually maintain good kidney health.
Everyone’s journey looks a little different. Some people never form stones, while others may have recurring episodes, especially if fluids are low or during illness. Ask about early symptoms of Xanthinuria type I that deserve attention—such as sudden side or back pain, blood in the urine, burning with urination, fever, or nausea—so you know when to seek care. Understanding the prognosis can guide planning and help you and your care team tailor a plan that fits your lifestyle. If your family is considering testing, genetic testing can sometimes provide more insight into prognosis, especially for relatives who may be at risk.
Long-term effects
Xanthinuria type I is a rare inherited condition that mostly affects the urinary tract over time, especially through stone formation. Long-term effects vary widely, and some people never develop symptoms. Early symptoms of Xanthinuria type I can include flank pain, blood in the urine, or passing sandy crystals in urine. Overall outlook is often good, particularly when kidney function stays stable across the years.
Many people never develop noticeable problems and feel well for years. Routine tests may be the first clue, showing very low uric acid.
Xanthine stones can form in the kidneys or ureters and tend to come back. They may start in childhood or young adulthood and vary in size and number.
Stones can lodge in the ureter and block urine flow. This can trigger infections and cause kidney swelling and severe colicky pain.
Repeated blockages and infections can gradually harm the kidneys. A small subset may develop chronic kidney disease over time.
How is it to live with Xanthinuria type i?
Living with xanthinuria type I often means feeling well day to day but staying mindful about kidney health. Many people have no symptoms for years, yet the low uric acid and buildup of xanthine can lead to kidney stones, flank pain, blood in the urine, or urinary infections, so hydration, a moderated purine intake, and regular check-ins become part of routine life. Family members and partners may get involved by helping plan stone-preventive habits—like keeping water nearby, choosing lower‑purine proteins, and watching for early signs of urinary trouble—without restricting normal activities. With guidance from a healthcare team, most people continue school, work, exercise, and travel, adjusting a few habits to protect their kidneys and prevent complications.
Treatment and drugs
Xanthinuria type I is usually managed by lowering the amount of xanthine your body has to handle and by protecting the kidneys. Treatment often looks different for each person, but most people are advised to drink plenty of fluids (aiming for at least 2–3 liters or about 68–100 ounces a day, unless your doctor says otherwise) and to follow a low‑purine diet to reduce xanthine production. Doctors may also suggest urine alkalinization (making the urine less acidic) to help keep xanthine from crystallizing, and they’ll monitor kidney health with periodic urine tests and imaging. There isn’t a medicine that replaces the missing enzyme in Xanthinuria type I, and drugs like allopurinol are generally avoided because they can raise xanthine levels, so care focuses on prevention and prompt treatment of stones or blockages. Ask your doctor about the best starting point for you, especially if you’ve had kidney stones, pain, or blood in the urine.
Non-drug treatment
Living with xanthinuria type i often means focusing on stone prevention in everyday life—what you drink, what you eat, and how you manage illness or heavy exercise. Non-drug treatments often lay the foundation for keeping kidneys healthy and preventing painful blockages. A few steady habits, plus regular check-ins, can lower the chance of stones forming. Care teams usually tailor these steps by age, activity level, and kidney history.
Limiting purine-rich foods helps reduce xanthine buildup that can form stones. Many avoid organ meats and certain fish, while choosing more plant-forward proteins.
Drinking enough water dilutes xanthine in urine and helps prevent crystals from sticking together. Adults are often advised to aim for about 2–3 liters (68–101 oz) daily, with extra on hot days or during workouts.
Vomiting, fever, or diarrhea can quickly dehydrate you and raise stone risk in xanthinuria type i. If you cannot keep fluids down, contact your care team early to discuss oral rehydration or IV fluids.
A dry overnight stretch can allow crystals to form. A glass of water before bed, and a small drink if you wake to use the bathroom, may help keep urine dilute.
Your genes may have an impact on how drugs work for you
Think of treatment as a set of tools that fit differently depending on your genes. In xanthinuria type I, variants in XDH can change drug handling and stone risk, so clinicians tailor choices and doses, sometimes avoiding xanthine-raising medicines to prevent complications.
Pharmacological treatments
Treatment focuses on preventing xanthine kidney stones and easing stone passage; there’s no enzyme replacement to correct the underlying enzyme gap in Xanthinuria type i. Medicines for this condition mainly aim to alkalinize urine so xanthine dissolves better, and to manage pain during stone episodes. Not everyone responds to the same medication in the same way. Drugs that block xanthine oxidase, like allopurinol or febuxostat, are generally avoided because they can raise xanthine levels and worsen stones.
Helps alkalinize urine so xanthine is more soluble and less likely to crystallize. Among medications for Xanthinuria type i, it’s often used to keep urine closer to alkaline levels. Your care team may monitor potassium levels and kidney function.
An alternative alkali if potassium citrate isn’t suitable. It can increase sodium load and cause bloating, so blood pressure and fluid status may be checked. Doses are adjusted to maintain urine on the alkaline side.
Can relax the ureter to help pass a stone during an acute episode. It’s typically used short term and may cause lightheadedness or low blood pressure. Take it in the evening if dizziness is an issue.
Pain relief during renal colic can reduce inflammation and improve comfort. NSAIDs like ibuprofen are effective but should be limited if kidney function is reduced or if you have ulcers. Acetaminophen is an alternative when NSAIDs aren’t advised.
Genetic influences
For most families, the condition traces back to a single gene that affects how the body clears xanthine, a natural waste product. Some conditions are passed down through families (inherited disorders). Xanthinuria type I happens when both copies of a gene called XDH don’t work well; parents are usually healthy carriers who each pass along one altered copy. This pattern means a child has a higher chance of being affected if both parents carry the change, but carriers themselves usually have no symptoms. How strongly it shows up can vary—some people live with few or no issues, while others develop kidney stones or urinary crystals early in life. Genetic testing can confirm changes in XDH and help guide care, especially when early symptoms of Xanthinuria type I—like kidney stones in childhood—appear in more than one relative.
Is Xanthinuria type i genetic?
Genetics are central in Xanthinuria type i. It’s a rare inherited condition caused by variations in the XDH gene, usually passed in an autosomal recessive pattern. Genetic testing confirms diagnosis, guides family counseling, and helps identify carriers and at‑risk relatives.
Pharmacogenetics—how genetics influence drug effects
Some common gout medicines and certain immune‑suppressing drugs can act differently in people with Xanthinuria type i. Genes can influence how quickly you clear certain medicines; in this condition, changes in the XDH gene leave little or no xanthine oxidase, the enzyme those drugs rely on. That means xanthine oxidase blockers such as allopurinol or febuxostat are usually not helpful and may increase xanthine levels, so they’re typically avoided.
When medicines like azathioprine or 6‑mercaptopurine are needed, the lack of xanthine oxidase can slow their breakdown and raise the risk of side effects, so doctors may choose alternatives, start at a lower dose, and monitor blood counts more closely. Confirming the diagnosis genetically can help tailor medication choices for Xanthinuria type i and flag drug–gene interactions in your record. Share your diagnosis with every prescriber and pharmacist so they can plan safe, effective treatment.
Interactions with other conditions
Living with Xanthinuria type i alongside other health issues can change how symptoms show up day to day, especially for the kidneys and muscles. Because early symptoms of Xanthinuria type i can be subtle, it may be mistaken for gout or other causes of kidney stones, and this matters: medicines that block xanthine oxidase (like allopurinol or febuxostat) aren’t helpful here and can raise xanthine levels, which may increase stone risk. If kidney disease is also present—or during bouts of dehydration from a stomach bug or heavy exercise—stones can form or grow faster and make blockage or pain more likely. People who need thiopurine medicines (such as azathioprine or 6‑mercaptopurine) for conditions like inflammatory bowel disease or certain leukemias may be more sensitive to these drugs because the body’s usual breakdown pathway is reduced, so lower doses or closer monitoring are often needed. Urinary tract infections can occur with stones; an infection may improve only after the blockage is relieved. Ask if any medications for one condition might interfere with treatment for another.
How genes can cause diseases
Humans have more than 20,000 genes, each carrying out one or a few specific functions in the body. One gene instructs the body to digest lactose from milk, another tells the body how to build strong bones and another prevents the body's cells from beginning to multiply uncontrollably and developing into cancer. As all of these genes combined are the building instructions for our body, a defect in one of these genes can have severe health consequences.
Through decades of genetic research, we know the genetic code of any healthy/functional human gene. We have also identified that in certain positions on a gene, some individuals may have a different genetic letter from the one you have. We call these hotspots "Genetic Variations" or "Variants" in short. In many cases, studies have been able to show that having the genetic letter "G" in the position makes you healthy, but having the letter "A" in the same position disrupts the gene function and causes a disease. Genopedia allows you to view these variants in genes and summarizes all that we know from scientific research, which genetic letters (Genotype) have good or bad consequences on your health or on your traits.
History
Throughout history, people have described unusually dark, gritty urine and kidney troubles that clustered in certain families, long before anyone knew why. Community stories often described the condition as stones appearing early in life or recurring bouts of flank pain that baffled local healers. For many, this meant a healthy child who suddenly passed sand-like crystals, then years later developed kidney stones again.
First described in the medical literature as a disorder with low uric acid and high xanthine in urine, xanthinuria type I was initially pieced together from these puzzling patterns. Early clinicians noticed that some people with frequent stones didn’t fit the usual gout picture. Tests showed strikingly low uric acid levels in blood and urine, which pointed researchers toward a different chemical pathway. As lab tools improved in the mid-20th century, scientists traced the issue to a missing enzyme step that normally helps the body break down purines, the building blocks in many foods and our own cells.
From early theories to modern research, the story of xanthinuria type I moved from bedside observations to enzyme assays and, eventually, to genetics. Investigators identified that the enzyme xanthine oxidoreductase was absent or barely working in this condition, leading xanthine to build up and form crystals and stones. Advances in genetics confirmed that changes in the XDH gene can disrupt this enzyme, explaining why some families saw the condition repeat across generations. This shift—from symptom patterns to precise molecular causes—helped separate xanthinuria type I from other look-alike conditions, including rarer forms that involve additional enzymes.
Over time, descriptions became more nuanced. Clinicians learned that not everyone with xanthinuria type I has dramatic symptoms; some people are found by chance during routine blood work showing very low uric acid. Others first come to care with kidney stones in adolescence or adulthood. Historical differences highlight why careful testing matters, since treatment and advice—like hydration and dietary guidance—depend on recognizing the exact type.
In recent decades, awareness has grown as laboratories adopted reliable tests to measure purine breakdown and as genetic testing became more accessible. Reports now include people from many regions, showing that xanthinuria type I exists worldwide, even if it remains uncommon. Knowing the condition’s history helps explain today’s approach: clinicians look for the classic lab pattern, confirm the enzyme or gene finding when possible, and use that information to guide long-term care and family counseling.